Expert Consultations: Real-World Answers

Drug-Induced Movement Disorders: The Clinical Essentials – Interview

Published on March 1, 2021 Expired on April 1, 2025

Guest

Mohan Gautam

To unlock this audio you need to become a Silver, Gold, Silver extended or Gold extended Member.

Check Our CME Program

Downloads for Offline Access

Download Audio File (MP3)

Interview Highlights

Propranolol, a beta-blocker, is the first-line treatment for akathisia, and the dose will be dependent on each population.
Anticholinergics for drug-induced EPS symptoms will be required for as long as the patient is on the primary agent causing the side effect. None of them has a greater efficacy over the other.
VMAT2 inhibitors are useful for tardive syndromes.

Text Version

This edition of Psychopharmacology Institute’s Expert Consultations features Gregory Pontone, M.D. Dr. Pontone is the Director of the Parkinson’s Disease Neuropsychiatry Clinic at Johns Hopkins University. In this interview, we will discuss drug-induced movement disorders.

Mohan Gautam, D.O.: There are 4 main types of drug-induced movement disorders: Akathisia, extrapyramidal symptoms (EPS), tardive syndromes, and acute dystonia. Could you describe how patients

Unlock this Expert Consultation and earn 0.50 CMEs
Become a Silver, Gold, Silver extended or Gold extended Member.

Get Instant Access

Already have an account? Sign in

Learning Objectives:

After completing this activity, the learner will be able to:

Identify different drug-induced movement disorders.
Discuss the possible mechanisms that explain the phenomenology.
Summarize appropriate treatment options for each of these according to patients' profiles.

Original Release Date: 03/01/2021

Review and Re-release Date: 03/01/2024

Expiration Date: 04/01/2025

Expert: Gregory Pontone, M.D.

Medical Editors: Mohan Gautam, M.D., Jessica Diaz, M.D.

Relevant Financial Disclosures:

The following planners, faculty, and reviewers have the following relevant financial relationships with commercial interests to disclose:

Dr. Pontone has disclosed the following relationships:

Acadia Pharmaceuticals Inc: Consulting

All of the relevant financial relationships listed for these individuals have been mitigated.

Contact Information: For questions regarding the content or access to this activity, contact us at support@psychopharmacologyinstitute.com

Instructions for Participation and Credit:

Participants must complete the activity online during the valid credit period that is noted above.

Follow these steps to earn CME credit:

View the required educational content provided on this course page.
Answer the quiz for promoting retention of knowledge.
Complete the Post Activity Evaluation for providing the necessary feedback for continuing accreditation purposes and for the development of future activities. NOTE: Completing the Post Activity Evaluation after the quiz is required to receive the earned credit.
Download your certificate.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of Medical Academy LLC and the Psychopharmacology Institute. Medical Academy is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement

Medical Academy designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Gregory Pontone, M.D., M.H.S.